NCT00489866

Aripiprazole Augmentation of Antidepressants in PTSD

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Durham VA Medical Center · Federal
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The proposed investigation will determine the therapeutic potential of aripiprazole augmentation to a stable antidepressant regimen for reducing posttraumatic stress disorder (PTSD) symptoms, cognitive symptoms, psychotic symptoms, and depressive symptoms in veterans with PTSD.

Conditions

• PTSD

Interventions

Type	Name	Description
DRUG	Aripiprazole	Aripiprazole: 5 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-10 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-15 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-20 mg taken once a day orally for 2 weeks
DRUG	Placebo	Same as active drug.

Timeline

• Start date: 2007-03-01
• Primary completion: 2008-09-01
• Completion: 2014-12-01
• First posted: 2007-06-21
• Last updated: 2015-03-31
• Results posted: 2012-03-28

Locations

1 site across 1 country: United States